Darapladib - CAS# 356057-34-6 205728 26]nonacosa-8(13)

26]nonacosa-8(13)

Di Carlo M

The induction of Cryj1-dependent IgE synthesis mediated by SN-4 is suppressed in a concentration-dependent manner by Suplatast tosilate (1 and 10 µg/ml) in autologous B cells

Mitoxantrone induces DNA fragmentation and the proteolytic cleavage of poly(ADP-ribose) polymerase (PARP)

Kurokawa T

Darapladib - CAS# 356057-34-6 205728 26]nonacosa-8(13)Darapladib, also known as SB 480848, is a reversible lipoprotein associated phospholipase A2 (Lp PLA2) inhibitor with IC50 of 0. 25 nM, which is in Phase 3 trials. Recent studies showed that risk of major coronary events not reduced by darapladib therapy. In patients with stable coronary heart disease, darapladib did not significantly reduce the risk of the primary composite end point of cardiovascular death, myocardial infarction, or stroke. Product